Capmatinib
Capmatinib is an oral targeted anticancer medicine belonging to the kinase inhibitor class, used to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation causing MET exon 14 skipping. It works by inhibiting the MET receptor tyrosine kinase, which can contribute to cancer cell growth, survival, and spread. Capmatinib is available as oral tablets and is prescribed based on appropriate molecular testing and specialist assessment. Common side effects include swelling of the hands or feet, nausea, vomiting, fatigue, musculoskeletal pain, cough, and reduced appetite. Important risks include liver toxicity, inflammation of the lungs (interstitial lung disease or pneumonitis), pancreatic enzyme abnormalities, and photosensitivity. Treatment requires regular medical monitoring, and patients should promptly report new breathing difficulties, persistent cough, yellowing of the skin or eyes, or severe abdominal pain.
Capmatinib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Capmatinib, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Capmatinib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Capmatinib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
